Dizal to Unveil ZEGFROVY Data at WCLC 2026 in Seoul

The upcoming presentations, scheduled for September 12–15, focus on two core developments for the sunvozertinib-based treatment. Prof. Chang Chen will detail efficacy and safety results from a study evaluating the drug as an adjuvant treatment for resected stage IB-IIIB non-small cell lung cancer patients harboring EGFR exon 20 insertion mutations. Preliminary observations indicate a manageable safety profile, prompting the initiation of a randomized pivotal study.

Simultaneously, Prof. Yongchang Zhang is set to provide updated Phase 2 data on the use of ZEGFROVY in combination with Anlotinib. This chemotherapy-free regimen is being investigated as a first-line treatment for patients with EGFR-sensitizing and co-mutations, showing consistent anti-tumor activity. These disclosures coincide with Dizal’s ongoing efforts to secure first-line approval for ZEGFROVY, with applications currently under review by both the U.S. FDA and China’s CDE. The company’s broader strategic landscape remains in flux following a July agreement to grant AstraZeneca global development and commercialization rights, a transaction expected to conclude by the end of 2026.